Solvay Ventures was among the participants in a series A round for 3D-printed medical technology developer PrinterPrezz.

PrinterPrezz, a US-based developer of medical-focused 3D printing technology, closed a $16m series A round yesterday that included Solvay Ventures, the corporate venturing arm of chemicals producer Solvay.

The round was led by investment firm D.One Vision Management’s DOV Singularity Fund and also featured Berkeley Catalyst Fund, the venture capital unit aligned to University of California (UC) Berkeley, as well as VC firm Boutique Venture Partners.

Founded in 2018, PrinterPrezz combines 3D printing, design and prototyping technology with its nanotechnology…